Tags: psoriasis | drug | approve | FDA | ixezizumab

FDA Approves New Drug for Psoriasis

FDA Approves New Drug for Psoriasis
(Copyright DPC)

Wednesday, 23 March 2016 08:39 AM

U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co to treat adults with moderate to severe cases of the skin condition plaque psoriasis.

The injectable biotech medicine known chemically as ixekizumab will be sold under the brand name Taltz, the Food and Drug Administration said.

Taltz works by blocking a protein that causes inflammation, which is believed to play a role in development of the autoimmune disorder characterized by red skin and thick, unsightly, scaly white patches.

In large, late-stage clinical trials, ixekizumab led to significant skin clearing compared with a placebo and also helped patients who did not respond to Amgen Inc's blockbuster treatment Enbrel.

"Today’s approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition,” Julie Beitz, from the FDA's Office of Drug Evaluation, said in a statement.

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co to treat adults with moderate to severe cases of the skin condition plaque psoriasis. The injectable biotech medicine known chemically as ixekizumab will be sold under the brand name...
psoriasis, drug, approve, FDA, ixezizumab
150
2016-39-23
Wednesday, 23 March 2016 08:39 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved